Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade

Chronological Source Flow
Back

AI Fusion Summary

Spyre Therapeutics shares hit a new 52‑week high after Robert W. Baird raised its target from $65 to $90. The stock opened at $67.68, closed at $63.27, trading near $75.00. Mizuho and Leerink Partners upgraded the stock.
#SPYRE_THERAPEUTICS #NASDAQ_SYRE #ANALYST_UPGRADE #PRICE_TARGET #52_WEEK_HIGH #STOCK_MOVEMENT
15/04 09:19 defenseworld.net
8 Πηγές

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade

PRICE ARTICLESCOMPANIESPOLITICS
15/04 09:50 defenseworld.net

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 12-Month High on Analyst Upgrade

POLITICSCOMPANIESPRICE ARTICLES
15/04 10:09 defenseworld.net

AdaptHealth (NASDAQ:AHCO) Sets New 1-Year High on Analyst Upgrade

COMPANIESPRICE ARTICLESECONOMYPOLITICS
15/04 10:37 defenseworld.net

Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

POLITICSCOMPANIESANALYST ARTICLES - US
15/04 11:09 defenseworld.net

Royal Bank Of Canada Issues Positive Forecast for Enerflex (NYSE:EFXT) Stock Price

COMPANIESECONOMYPOLITICSANALYST ARTICLES - US
15/04 11:25 defenseworld.net

Royal Bank Of Canada Issues Positive Forecast for Baker Hughes (NASDAQ:BKR) Stock Price

POLITICSANALYST ARTICLES - USECONOMYCOMPANIES
15/04 11:38 defenseworld.net

Allogene Therapeutics (NASDAQ:ALLO) Price Target Raised to $9.00 at Robert W. Baird

COMPANIESPOLITICSANALYST ARTICLES - US
15/04 11:56 defenseworld.net

Susquehanna Issues Positive Forecast for Intel (NASDAQ:INTC) Stock Price

ANALYST ARTICLES - USPOLITICSCOMPANIES
Comments
Loading...
0